NP202 for Treatment of Post -STEMI Left Ventricular Systolic Dysfunction
NCT02557217 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120
Last updated 2017-06-28
Summary
NP202 is an experimental drug being developed by Armaron Bio Pty Ltd for potential use as a treatment for people after they have had a heart attack (MI).
Conditions
- ST Elevation Myocardial Infarction
Interventions
- DRUG
-
NP202
Active
- OTHER
-
Placebo
Placebo
Sponsors & Collaborators
-
Armaron Bio Pty Ltd
lead INDUSTRY
Principal Investigators
-
Grant McLachlan · Sponsor GmbH
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-10-31
- Primary Completion
- 2017-12-31
- Completion
- 2018-02-28
Countries
- Australia
Study Locations
More Related Trials
-
A Randomized, Placebo-Controlled, Double-Blind, Double Dummy Trial To Determine The Relative Effect Of Pm101 Versus Placebo And Amiodarone IV On Blood Pressure In Subjects With Stable Congestive Heart Failure
NCT00739193 ·Status: WITHDRAWN ·Phase: PHASE2
-
Evaluation of Vepoloxamer in Chronic Heart Failure
NCT02596477 ·Status: TERMINATED ·Phase: PHASE2
-
Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy
NCT01151137 ·Status: TERMINATED ·Phase: PHASE3
-
Flecainide Acetate Inhalation Solution for Cardioversion of Recent-Onset, Symptomatic Atrial Fibrillation
NCT05039359 ·Status: TERMINATED ·Phase: PHASE3
-
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)
NCT05327855 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491
NCT03062956 ·Status: COMPLETED ·Phase: PHASE1
-
A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy
NCT06979362 ·Status: RECRUITING ·Phase: PHASE2
-
A Research Study Comparing CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Reduced/Mildly Reduced Ejection Fraction and Left Ventricular Hypertrophy
NCT06979375 ·Status: RECRUITING ·Phase: PHASE2
-
The Effects of Ambrisentan on Exercise Capacity in Fontan Patients
NCT01971580 ·Status: COMPLETED ·Phase: PHASE4
-
The Effect of EPLerenone on Ischemia Reperfusion Injury in Human myoCARDium
NCT02118753 ·Status: COMPLETED ·Phase: NA
-
Ambrisentan in Single Ventricle
NCT02080637 ·Status: COMPLETED ·Phase: PHASE2
-
Prevention of Coronary Microvascular Dysfunction Post-PCI by Intracoronary Nicardipine
NCT03184155 ·Status: WITHDRAWN ·Phase: EARLY_PHASE1
-
Evaluation of Two Different Regimens of the Antiarrhythmic Drug Amiodarone to Maintain Normal Sinus Rhythm After Electrical Cardioversion in Patients With Persistent Atrial Fibrillation
NCT07273994 ·Status: RECRUITING ·Phase: PHASE4
-
An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia
NCT05117346 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
The Effect of Nicorandil on Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion
NCT05087797 ·Status: COMPLETED ·Phase: PHASE4
-
Dronedarone in Pacemakers Patients With Paroxysmal Atrial Fibrillation
NCT01070667 ·Status: UNKNOWN ·Phase: PHASE4
-
A Research Study on the Effects of NNC0537-1482 in Participants With Heart Failure
NCT07218627 ·Status: RECRUITING ·Phase: PHASE1
-
A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure
NCT01357850 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of TRC041266 in Patients With Heart Failure, LVEF ≥40%, Diastolic Dysfunction and Type 2 Diabetes Mellitus
NCT04507347 ·Status: WITHDRAWN ·Phase: PHASE3
-
The Effect of Early Administration of Dapagliflozin in STEMI Patients With LV Systolic Dysfunction
NCT05045274 ·Status: UNKNOWN ·Phase: NA
-
Prospective Observation of Cardiac Safety With Proteasome Inhibition
NCT02178579 ·Status: COMPLETED
-
Safety and Efficacy Study of PB127 Ultrasound Contrast Agent in Patients With Suspected Coronary Artery Disease 007
NCT00595673 ·Status: COMPLETED ·Phase: PHASE3
-
EMpagliflozin to PREvent worSening of Left Ventricular Volumes and Systolic Function After Myocardial Infarction
NCT05020704 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Effects of Dronedarone on Atrial Fibrillation Burden in Subjects With Permanent Pacemakers
NCT01135017 ·Status: TERMINATED ·Phase: PHASE4
-
A Study of the Efficacy and Safety of Danicamtiv in Participants With Symptomatic Genetic and Familial Dilated Cardiomyopathy
NCT07210723 ·Status: RECRUITING ·Phase: PHASE2/PHASE3